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ABSTRACT
Background Wolfram syndrome (WFS) is a rare 
disorder characterised by childhood- onset diabetes 
mellitus and progressive optic atrophy. Most patients 
have variants in the WFS1 gene. We undertook functional 
studies of WFS1 variants and correlated these with WFS1 
protein expression and phenotype.
Methods 9 patients with a clinical diagnosis of WFS 
were studied with quantitative PCR for markers of 
endoplasmic reticulum (ER) stress and immunoblotting of 
fibroblast protein extracts for WFS1 protein expression. 
Luciferase reporter assay was used to assess ATF-6 
dependent unfolded protein response (UPR) activation.
Results 6 patients with compound heterozygous 
nonsense mutations in WFS1 had no detectable 
WFS1 protein expression; 3 patients with missense 
variants had 4%, 45% and 48% WFS1 protein 
expression. One of these also had an OPA1 mutation 
and was reclassified as autosomal dominant optic 
atrophy- plus syndrome. There were no correlations 
between ER stress marker mRNA and WFS1 protein 
expression. ERSE- luciferase reporter indicated 
activation of the ATF6 branch of UPR in two patients 
tested. Patients with partial WFS1 expression showed 
milder visual acuity impairment (asymptomatic or 
colour blind only), compared with those with absent 
expression (registered severe vision impaired) 
(p=0.04). These differences remained after adjusting 
for duration of optic atrophy.
Conclusions Patients with WFS who have partial WFS1 
protein expression present with milder visual impairment. 
This suggests a protective effect of partial WFS1 protein 
expression on the severity and perhaps progression of 
vision impairment and that therapies to increase residual 
WFS1 protein expression may be beneficial.
INTRODUCTION
Wolfram syndrome (WFS), also known by 
the acronym DIDMOAD (diabetes insipidus, 
diabetes mellitus, optic atrophy and deafness; 
MIM#222300), is a rare autosomal reces-
sive disease characterised by childhood- onset 
diabetes mellitus (DM) and optic atrophy (OA) 
associated with neuropathic bladder and neuro-
degeneration.1 2 The estimated prevalence is 1 in 
770 000 in the UK.1
WFS is one manifestation of WFS1- related 
disorders, caused by variants in the WFS1 gene.3 
Other manifestations include WFS1- related low- 
frequency sensorineural hearing loss (WFS1- 
related LFSNHL), characterised by congenital, 
non- syndromic, low- frequency sensorineural 
hearing loss, and WFS- like disease, characterised 
by sensorineural hearing loss, DM, psychiatric 
illness and variable OA, not limited to childhood 
presentation.4 Both WFS1- related LFSNHL and 
WFS- like disease are dominantly inherited.4–6
The WFS1 protein (MIM#606201) is located 
in the endoplasmic reticulum (ER) membrane.3 
One of its functions relates to the unfolded 
protein response (UPR) pathways, where it is 
upregulated in response to ER stress.7 ER stress 
occurs when the cellular demand for protein 
production exceeds the protein folding capacity 
in the ER.8 WFS1 is a negative regulator of the 
UPR.9 It binds to the ER stress sensor, ATF6, 
leading to its proteasomal degradation and 
preventing chronic activation of the UPR and 
cell death.9
The WFS1 gene is located on the short arm of 
chromosome 4 at position 16.1 (4p16.1).3 There 
are currently 309 reported disease- causing WFS1 
variants.5 Most variants occur in exon 8 with the 
majority being nonsense, duplications or deletions 
resulting in early stop codons or additional transla-
tion of previously non- coding DNA.5
Previous studies have shown that patients with 
WFS who had an in silico predicted complete loss 
of WFS1 protein function had an earlier onset of 
WFS,10 DM11 and OA,11 compared with patients 
who had predicted partial loss of WFS1 function. 
Other studies showed patients with classic WFS 
had worse visual acuity and reduced retinal nerve 
thickness compared with patients with autosomal 
dominant WFS- like syndrome.12 WFS1 protein 
expression was measured in a single patient with 
neonatal diabetes insipidus (DI) and unilateral optic 
disc hypoplasia.13 This patient was found to have 
reduced WFS1 protein expression, but as this was 
due to a segmental paternal heterodisomy of chro-
mosome 4, it is not clear whether other genetic 
defects were involved.
In the current study, we aimed to explore 
the functional consequences of known disease- 
associated variants as well as missense variants of 
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unknown significance in patients referred to our service with a 
clinical diagnosis of WFS.
METHODS
Patients
We defined WFS as the coexistence of childhood DM and OA 
(under 16 years).1 Patients were recruited from National Health 
Service England highly specialised national multidisciplinary 
service for WFS in Birmingham, UK, and participating in the 
EUROWABB registry (EU Rare Diseases Registry for Wolfram 
syndrome, Alström syndrome, Bardet- Biedl syndrome and 
other rare diabetes syndromes: http:// euro- wabb. org/).14 Clin-
ical symptoms were recorded, and severity was assessed using: 
glycated haemoglobin (HbA1C) for glycaemic control in DM; 
pure tone average calculated from 0.5, 1, 2 and 4 kHz and 
qualitative description of pure tone audiometry from 0.25 to 8 
kHz for measurement of hearing loss15; and logMAR value for 
visual acuity. Data were collated using IBM SPSS Statistics 25, 
and groups were compared for statistical analysis with Student’s 
t- test for parametric data and the Mann- Whitney U test for non- 
parametric data.
Gene variant analysis
Venous blood was collected for WFS1 gene sequencing. This 
was initially carried out by Sanger sequencing with an ABI 
3730 DNA sequencer, subsequently superseded by multiplex 
ligation- dependent probe amplification using ABI 3130 DNA 
sequencer and 3500 Genetic Analyzers. The following polymor-
phism prediction programmes were used for in silico analysis 
to predict the pathogenicity of WFS1 missense variants: SIFT,16 
PolyPhen-2,17 Mutation Taster18 and Provean.19
Fibroblast culture
Primary fibroblasts were cultured at the Human Biomaterials 
Resource Centre University of Birmingham. Fibroblasts from 
healthy individuals were purchased from the European Collec-
tion of Cell Cultures: control 1 (C1) was from a 70- year- old 
white European man; control 2 (C2) and control 3 (C3) were 
from 46- year- old and 28- year- old white European women, 
respectively. The fibroblasts were cultured in Advanced DMEM 
medium (Life Technologies), supplemented with 10% fetal 
bovine serum Biosera), Penicillin- Streptomycin and Gluta- MAX 
(Life Technologies) and grown in 37°C/5% CO2 incubators. 
Cultures were grown to 80% confluency before use for the func-
tional assays described below.
Quantitative PCR for WFS1 mRNA and markers of ER stress 
(BiP, CHOP and sXBP1)
RNA from fibroblasts of patients and controls was prepared 
following the TRIzol protocol (Invitrogen). DNA was removed 
using DNA free kit (Ambion), and cDNA was prepared with 
High Capacity cDNA Reverse Transcription kit (Applied Biosys-
tems). Quantitative PCR was performed using TaqMan Expres-
sion Assays (Applied Biosystems) for WFS1, BiP, CHOP and 
sXBP1. Results were calculated by delta- delta CT method and 
quantified as a percentage in relation to control levels. Experi-
ments were repeated at least four times, and results were anal-
ysed by Student’s t- test.
Immunoblotting for WFS1 protein expression
Fibroblasts from patients and controls were harvested in SDS 
lysis buffer (0.5M Tris pH7.0, 10% SDS, 25% glycerol). Ten 
micrograms of protein extract was run on SDS PAGE gels in 
Tris/glycine/SDS running buffer (Geneflow). Gel transfer to 
PVDF (Polyvinylidene difluoride) membrane was performed 
in Tris/glycine transfer buffer (Geneflow) at 90V for 1 hour. 
Incubation with primary anti- WFS1 antibody (Proteintech, 
rabbit polyclonal), at 1:1000 dilution in 5% milk/PBS- Tween, 
was performed overnight at 4°C. Secondary antirabbit antibody 
(Dako) was used at 1:20 000 for 1 hour at room temperature. 
Integrated optical density with Gene Tool software was used for 
quantification. WFS1 levels were quantified as a percentage in 
relation to control levels. Experiments were repeated four times, 
using two independently prepared sample extracts. Results were 
analysed by Student’s t- test.
Luciferase reporter assay for ATF6-dependent UPR activation
Plasmids
‘E1T’ plasmid was an ER stress- response element (ERSE) 
reporter plasmid that encoded firefly luciferase downstream of 
a putative ERSE enhancer within the pGL3 Promoter plasmid 
(Promega).20 The ERSE sequence was subcloned in triplicate 
using BglII and SmaI restriction sites.
The internal control plasmid was Renilla- reporter plasmid 
pRL- SV40 (Promega), which was used to normalise for trans-
fection efficiency.
Transfection and reporter assay
Fibroblasts from patients S02 and S10 were transfected with 
Fugene transfection reagent (Promega) and cotransfected with 
either: ‘E1T’ plasmid with the pRL- SV40 plasmid or pGL3 
control plasmid with pRL- SV40 plasmid.
Forty- eight hours after transfection, the cells were harvested 
in Passive Lysis Buffer (Promega), and luciferase activity was 
measured using the Dual Luciferase Reporter Assay System 
(Promega). Bioluminescence was detected using a Centro LB 960 
microplate luminometer (Berthold Technology). The results are 
presented as ‘relative luciferase activity’ (a ratio of the normalised 
value obtained for E1T plasmid to pGL3 control plasmid). This 
is a reflection of ER stress signalling and ATF6- dependent UPR. 
The mean values from at least four experiments were used and 
results analysed by Student’s t- test.
RESULTS
Clinical presentation
Nine patients with a clinical diagnosis of WFS from seven unre-
lated families were recruited. Patients S03 and S04 were siblings, 
as were patients S10 and S11 (figure 1A, table 1). There were 
six females and three males (age 17–32 years). The median age 
of onset of:DM was 6 years (range 3–10 years); OA was 6 years 
(4–14),;hearing loss was 8 years (birth–15); DI was 13 years 
(3–16) in five patients; and urinary dysfunction was 15.5 years 
(10–16) in six patients.
Variant analysis
The location of WFS1 variants detected is shown in figure 2, and 
details of WFS1 variant analysis are shown in table 2.
Compound heterozygous WFS1 mutations were found in 
seven patients. S03, S04, S09, S10 and S11 all had nonsense or 
frameshift variants, previously reported to be disease associated.5
S01 and S06 had nonsense and missense WFS1 variants in trans. 
The missense variant in S01 (c.505G>A;p.Glu169Lys) has been 
previously reported21 22 and predicted to be damaging by Poly-
Phen-2 and Provean. The missense variant in S06 (p.Pro428Arg) 
has also been previously reported5 and predicted to be damaging 
in all prediction programmes.
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Figure 1 Family pedigrees and functional data.
(A) Pedigrees of the 7 families reported in this study. All patients included in the study marked in grey. The age of onset of diabetes 
mellitus (DM) and optic atrophy (OA) stated. S02 had a de- novo mutation. For patient S07, OPA1 and WFS1 variants were found in all 
three generations in this family: S07’s maternal grandfather had isolated OA; S07’s mother had isolated OA and Type 1 DM. OA and 
DM in S07’s family represented by quarter stripes (OA) and quarter black (DM). All other patients inherited recessive alleles from each 
parent.
(B) Immunoblotting images and corresponding bar chart with standard error bars showing levels of WFS1 protein. WFS1 and beta- actin 
(BA) protein levels measured in fibroblast from patients with WFS and healthy controls. C1, C2, C3 = healthy controls; CAve: average of 
controls. WFS1 levels for CAve=100%. WFS1 protein was undetectable in patients: S03, S04, S06, S09, S10 and S11. WFS1 protein was 
reduced in S01, S02 and S07 by 96.2%, 53.3%, and 55.4% respectively in comparison to CAve. Analysis by Student's T- test.
(C) Bar chart with standard error bars showing quantitative PCR analysis of WFS1 mRNA, as percentage change when standardised with 
control. C=control. (n= 4) Analysis by Student's T- test.
(D) Bar chart with standard error bars showing quantitative PCR analysis of ER stress marker mRNA: BiP, CHOP and sXBP1, as 
percentage change, when standardised with control (C). (n=4). Dark grey bars indicate patient in the deficient WFS1 protein group, and 
the light grey bar indicates the patient is in the partial WFS1 protein group. Analysis by Student's T- test.
(E) Bar chart with standard error bars showing quantification of ATF6- dependent UPR activation by ERSE luciferase reporters, for SO2 
and S10, as a percentage change compared from control (C). (n=4) Analysis by Student's T- test.
ns: P >0.05; * P≤0.05; ** P ≤0.01; *** P≤0.001 compared with control samples
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Patient S02 had a missense variant (p.His313Tyr) that was ‘de 
novo’, that is, not present in the parents. The variant has been 
previously reported6 23 and shown to be disease associated and 
autosomal dominantly inherited.24 The other allele had a 6 bp 
duplication in a non- coding region, inherited from their asymp-
tomatic mother.
Patient S07 had a previously reported missense variant 
(c.1153G>A; p.Glu385Lys)5 25–27 and a wild type WFS allele. 
This variant was only predicted to be disease- associated in Muta-
tion Taster software. Due to a family history of OA in mother 
and maternal grandfather, a search was made for other genetic 
causes of OA. A disease- associated duplication (exon 4–8) in 
the OPA1 gene was subsequently identified (figure 1A). On 
further investigation, S07 was noted to have positive antibodies 
to glutamic acid decarboxylase (GAD), associated with type 1 
diabetes. Patient S07 was subsequently reclassified as autosomal 
dominant optic atrophy (DOA) with profound early- onset deaf-
ness and type 1 (autoimmune) diabetes.
WFS1 mRNA levels
Real- time PCR results (figure 1C) showed a 39.8% (SE±0.12) 
to 77.3% (SE±0.15) reduction in WFS1 mRNA expression in all 
patients with WFS compared with control samples.
WFS1 protein levels
The three controls had variable WFS1 protein levels (figure 1B), 
so the mean value was used for comparisons (CAve).
No WFS1 protein was detected on immunoblotting of fibro-
blasts from S03, S04, S06, S09, S10 and S11. Detectable but 
reduced expression of WFS1 protein was observed in fibroblasts 
from S01 (3.8%; SE±1.4; p<0.001), S02 (47.7%; SE±4.7 
p<0.02) and S07 (44.6%; SE±11.2 p<0.01), compared with 
CAve.
ER stress levels
There was a large variation in the expression of ER stress markers 
in all patients with WFS (figure 1D). S04, S10 and S11 displayed 
increased expression of at least one marker, although these did 
not all reach statistical significance. In patients S02, S03, S06, 
S07 and S09, the markers were unchanged or decreased.
There were no correlations observed between the mRNA 
levels of the ER stress markers and WFS1 protein expression or 
severity of WFS phenotype.
ATF6- dependent UPR activation was measured with ERSE- 
luciferase reporter in fibroblasts of patients S02 and S10. In both, 
the luciferase levels were increased under steady- state conditions 
by 63% (SE±6.5; p=0.03) and 74% (SE±11.3; p=0.001), 
respectively (figure 1E). This indicates the activation of the 
ATF6 branch of UPR.20 Both patients had similar profiles of 
UPR activation despite having differing levels of WFS1 protein. 
In the patient with WFS1 protein expression, this may reflect the 
dominant- negative effect of the p.His313Tyr gene variant.
Genotype–phenotype correlations
Patients who had no detectable WFS1 protein expression (the ‘defi-
cient WFS1 protein’ group) all had WFS1 variants that were either 
nonsense, frameshift or previously reported and had predicted 
disease- associated missense mutations on in- silico analysis. These six 
patients have the following median ages of onset: DM 5.5 years (range 
3–10 years); OA 5.5 years (4–9); DI 10.5 years (3–16); hearing loss 
8.5 years (4–13); urinary dysfunction 16 years (10–16). In terms of 
the disease severity, the median HbA1c was 63.4 mmol/mol (55.2–
79.8), the median hearing loss range was 77.5 dB (35–100) and the 
median logMAR value for current visual acuity was 2.0 (1.7–2.9).
The patients with ‘partial WFS1 protein’ possessed WFS1 missense 
variants that had differing results in pathogenicity on in- silico anal-
ysis. S07, who had an OPA1 variant, was reclassified as autosomal 
DOA with sensorineural deafness and type 1 DM and was excluded 
Figure 2 Schematic representation of WFS1 protein and variant locations.
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from this group for genotype–phenotype analysis. The other two 
patients have the following mean ages of onset: DM 3.8 years (range 
1.5–6.0 years); OA 11 years (8–14); DI 13 years (SO1 only); hearing 
loss 5 years (1.5–14); and urinary dysfunction at 14.5 years (14–15). 
The mean HbA1c was 72.1 mmol/mol (65.2–79.0), the mean 
hearing loss range was 65 dB (50–80) and the logMAR value for 
current visual acuity was 0.3 (0.2–0.4).
Comparing the two groups, there was a statistically significant 
difference in the severity of OA as measured by current logMAR 
score (p=0.04) (figure 3A), but not in the age of onset of OA 
(p=0.13) (online supplemental figure 1). The partial WFS1 protein 
group had better visual acuity on current logMAR value, meaning 
milder symptoms of OA. The degree of visual impairment remained 
markedly different between the groups, even after taking the dura-
tion of OA (from diagnosis) into account (figure 3B).
S01 has colour vision deficiency and up until the age of 19 years 
(2017) had visual acuity within the normal range but has recently 
been denied a driving licence. S02 has had long- standing asymp-
tomatic OA since the first examination and can read normal size 
text. The vision of S07 has been stable, with incremental changes to 
refractory prescriptions and right temporal retinal fibre layer loss, 
characteristic of patients with OPA1 DOA. This differs from WFS, 
which tends to produce diffuse OA.
By comparison, in the ‘deficient WFS1 protein’ group, all are 
registered severely visually impaired: requiring the use of Braille, 
computer speech software or size 72 font and/or using guide dogs.
There were no qualitative differences in the MRI brain 
reports between the two groups. All the patients had radiolog-
ical evidence of atrophy of optic nerve, chiasm and tracts, except 
patient S07 where MRI was unable to be undertaken.
There were no statistically significant differences in urinary 
dysfunction, mean levels of HbA1c or degree of hearing loss, nor in 
the age of onset of DM, OA, DI and hearing loss, between the groups 
(online supplemental figure 1) and (online supplemental table 1).
DISCUSSION
Correlation of WFS1 protein level and severity of OA
Data from a patient- reported outcomes measures survey 
completed by 48 patients with WFS in the UK revealed that 
vision impairment was the most important symptom affecting 
the quality of life (Barrett TG 2018, unpublished).
We have shown that the six patients with a clinical diagnosis 
of WFS, who are compound heterozygous for loss of function 
variants, or a missense variant, and predicted to be damaging 
in multiple protein prediction software programmes, have no 
detectable WFS1 protein expression. These patients had the 
onset of OA at a median age of 5.5 years, and progression to 
severe vision impairment (logMAR >1.0) within 11.4 years of 
onset.
Two patients with the WFS1 variants p.Glu169Lys and 
p.His313Tyr are associated with having residual WFS1 protein 
expression; their OA commenced at a median age of 11 years, 
and they have maintained only mildly or moderately reduced 
visual acuity (logMAR scores 0.5 and 0.2) despite having 8.4 
years mean duration of OA (figure 3B). The presence of residual 
WFS1 protein expression in patients S01 and S02 appears to 
be associated with a later onset as well as the markedly slower 
progression of visual impairment.
Given the rarity of WFS, the fact that this correlation was seen 
in both of the patients who we discovered to have residual WFS1 
Figure 3 Comparison of visual acuity data between groups.
(A) Box plot comparing LogMAR values between deficient (n=6) and partial WFS1 (n=2) protein groups; showing statistically significant 
difference (p=0.04). logMAR value (visual acuity logarithm of the minimum angle of resolution) is the magnification requirement, the 
higher the logMAR value, the worse the visual acuity (<1.0 mild- moderate visual impairment, 1.0-1.3 sight impaired (partial sighted) 
>1.3 severely sight impaired (blind). 40–42
(B) Scatter graph showing logMAR values of each patient corresponding to the duration of optic atrophy from the diagnosis of OA 
(irrespective of the age of diagnosis). Plots for patients in deficient WFS1 protein group shown in grey triangles (n=6); regression line 
is drawn between the patients in deficient WFS1 protein group (correlation of determination is 0.93). Plots for patients in partial WFS1 
protein group (SO1 + SO2) shown in white circles (n=2).
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levels, this will need to be investigated in other patients with 
residual WFS1 protein expression.
One patient (S07) was found to have OPA1 mutation and the 
heterozygous p.Glu385Lys WFS1 missense variant. Due to the 
possible confounding effect of the OPA1 mutation, S07 was not 
included in the genotype–phenotype analysis for OA. However, 
S07 was included in this study because the patient initially 
presented clinically with characteristics of WFS, with milder 
symptoms of OA. Even though S07 does not have classical WFS 
based on the genotype, the fact that the fibroblasts only had 
44.6% of WFS1 protein suggests that this WFS1 variant may 
confer some pathogenicity. Also, we cannot exclude the possi-
bility of an interaction between the WFS1 and OPA1 variants 
contributing to their OA. Therefore this patient was worthy of 
the further discussion below.
WFS1 variants and WFS mRNA and protein levels
Our results show that irrespective of WFS1 protein levels, all the 
patients have 33%–47% of WFS1 mRNA still present, including 
patients with nonsense mutations. This suggests that WFS1 
mRNA from these variants may not have been destroyed by 
nonsense- mediated mRNA decay (NMD). This is consistent with 
reports of patients with WFS harbouring homozygous Trp700X 
variants and the Phe343fsX396 variant who did not trigger 
NMD.28 According to the rule that to trigger NMD, the prema-
ture stop codons must lie 50–55 nucleotides upstream from the 
last exon/exon junction29; only premature stop codons upstream 
of the amino acid position 269 in exon 8 of WFS1 should cause 
NMD. All nonsense variants in our study patients were down-
stream of this position.
The absence of any detectable truncated WFS1 proteins in 
the deficient WFS1 protein group, by immunoblotting, is likely 
a result of the instability of these abnormal proteins. This is 
consistent with a report that demonstrated no detectable WFS1 
protein in a patient harbouring homozygous nonsense mutations 
and markedly reduced WFS1 protein in a patient harbouring 
missense and nonsense variants. Results from pulse- chase exper-
iment suggest that these WFS1 mutations resulted in an unstable 
WFS1 protein with a markedly reduced half- life.28
ER stress response
Of the patients with reduced WFS1 residual protein level (S02 
and S07), we did not detect any consistent increase in any ER 
stress markers. Protein expression from the wild type WFS1 
allele appears to offer sufficient protection against ER stress. 
This is consistent with the expected WFS1 protein expression 
in obligate WFS1 variant carriers who do not express a WFS 
phenotype.
WFS1 protein is a negative regulator of the ATF6 transcrip-
tion factor, and in WFS1 depletion, hyperactivation of the ATF6 
pathway was described.9 We demonstrated activation of ATF6 
pathway in fibroblasts of patients S02 and S10 in our lucif-
erase reporter assay. In S10, this is likely due to depletion of 
WFS1 protein, which is consistent with the previous report.9 In 
S02, the activation of the ATF6 pathway likely resulted from a 
dominant- negative effect of the c.937C>T;p.His313Tyr allele. 
Functional assays have shown that mutant p.His313Tyr WFS 
protein significantly increases ER stress and shows autosomal 
dominant inheritance.23 24
The analysis of the other ER stress markers between the groups 
proved inconclusive. Fibroblasts are cells that are not known to 
harbour pathology in patients with WFS. Interestingly, impair-
ment of calcium homeostasis was reported in WFS1- deficient 
fibroblasts from patients with WFS.30 We have previously 
demonstrated evidence of ER stress and impaired ER calcium 
homeostasis in more disease- relevant tissues.31
WFS1 c.505G>A;p.Glu169Lys variant
Patient S01 has a compound heterozygous nonsense 
(c.1558C>T;p.Gln520X) and a previously reported missense 
(c.505G>A;p.Glu169Lys) WFS1 variant.32 This genotype 
resulted in a 96.2% reduction of WFS1 protein levels, suggesting 
that this missense mutation resulted in marked instability of the 
WFS1 protein.
S01 has classical features of WFS. After having initial isolated 
colour vision reduction, S01 progressed to using an iPad to 
photograph the whiteboard in classrooms. The patient was 
initially considered for a driving licence but was turned down 
due to the vision impairment.
The consequences of this genotype, resulting in 3.8% residual 
WFS1 protein, appear to correlate with a slower progression 
of visual impairment, compared with patients with a complete 
absence of WFS1 protein expression.
WFS1 c.937C>T;p.His313Tyr variant
Patient S02 has a ‘de novo’ WFS1 c.937C>T;p.His313Tyr variant 
as well as a duplication in an untranslated region of WFS1. This 
patient had profound early- onset hearing loss and DM, both by 
18 months. OA was diagnosed at 8 years but remains asymptom-
atic. We have shown a 52.3% reduction in WFS1 protein levels 
in the fibroblasts (figure 1B). Our results from ER stress lucif-
erase reporter transfected to fibroblasts from S02 also demon-
strated increased ATF6- dependent UPR activation (figure 1D).
There have been two other reported cases of unrelated 
patients with WFS who were also found to have a single de novo 
His313Tyr WFS1 variant, respectively.6 23 Interestingly, they 
also developed profound early hearing loss by 2 years of age, 
DM by 4 years of age and had learning impairment.6 His313Tyr 
was subsequently shown to be disease associated in an auto-
somal dominant manner in a cell model for WFS.24 The clin-
ical features in all three of these patients with His313Tyr variant 
are typical of patients with autosomal dominant WFS, with a 
spectrum that includes neonatal/infancy onset DM, congenital 
cataracts and sensorineural deafness.23 Our patient has not yet 
shown any evidence of cataracts.
S02 also has a six base pair duplication (c.1709_14dupT-
GCCCC) in the 5′ untranslated region of exon 1. This was 
inherited from the patient’s mother, who is an asymptomatic 
carrier. The duplication is located within the WFS1 minimal 
promoter region and a critical GC box. Deletions in this area 
affect transcription factor binding and reduce gene transcrip-
tion.33 However, the effect of this particular duplication on 
WFS1 promoter activity is unknown. Therefore, we are unable 
to determine to what degree this six base pair duplication or 
the p.His313Tyr variant had on the 52.3% reduction in WFS1 
protein levels we observed.
WFS1 c.1153G>A;p.Glu385Lys variant
Patient S07 has a heterozygous WFS1 missense variant 
(c.1153G>A;p.Glu385Lys) and a heterozygous OPA1 duplica-
tion variant (duplication of exons 4–8) found following further 
genetic screening. Similar duplications within OPA1 have been 
reported as disease associated.34–36
S07 had initial clinical features fulfilling clinical criteria for 
WFS including DM, OA and hearing loss.
9Hu K, et al. J Med Genet 2021;0:1–10. doi:10.1136/jmedgenet-2020-107257
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This patient was born with profound sensorineural hearing 
loss due to non- functioning cochlear, requiring bilateral cochlear 
implants. Weakly positive anti- GAD65 antibodies suggested 
a possible autoimmune cause of DM. OA was first recognised 
at 4 years. S07 has had a slow progression of OA, requiring 
only incremental changes to prescription glasses. This patient’s 
current corrected visual acuity is borderline for a private vehicle 
driving licence.
After the family genetic screening, it was found that this patient 
inherited both the OPA1 and WFS1 variants from their mother 
and maternal grandfather (figure 1A).5 The patient’s mother had 
type 1 DM since 16 years of age. Subsequently, after positive 
OPA1 screening, bilateral temporal OA was seen at 39 years of 
age, with logMAR 0.2 acuity in each eye. Maternal hearing is 
normal, and she is otherwise well. Maternal grandfather has 
isolated bilateral OA but no diabetes.
We conclude that the phenotype of S07 may best be explained 
as autosomal DOA due to the OPA1 variant, with associated 
hearing loss (DOA- plus syndrome, seen in 20% of cases of 
DOA).37 S07 has temporal OA and nerve fibre layer loss in a 
characteristic pattern for OPA1 DOA.38 Interestingly, this partic-
ular OPA1 variant has not been previously reported to result 
in a DOA- plus phenotype.39 Their autoimmune type 1 DM is 
assumed to be coincidental.
The c.1153G>A;p.Glu385Lys WFS1 missense variant that we 
detected has not been previously reported in patients with WFS 
and is currently of unknown significance. However, it has been 
reported in patients without WFS, who had either isolated OA 
or sensorineural deafness.25–27 It remains a possibility that there 
may be an interaction between this WFS1 variant and the OPA1 
duplication that could have contributed to S07’s development of 
sensorineural deafness and OA.
We have also shown there was a 55.4% reduction in WFS1 
protein levels observed in S07’s fibroblasts. Therefore, we spec-
ulate that this WFS1 variant may result in classical WFS if in 
combination with another loss of function WFS1 variant.
Conclusion
We have shown that residual WFS1 protein levels in patients 
with WFS show milder visual impairment and slower progres-
sion compared with patients with absent protein expression. 
Even a minimal WFS1 protein expression of 3.8% of wild type 
seems to have an ameliorating effect.
Our findings suggest that there may be a therapeutic benefit 
in strategies to increase residual WFS1 protein levels for those 
patients who retain some protein expression.
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